Clinical significance of toll-like receptor 3, 4, and 9 in gastric cancer

Journal of Immunotherapy

Volumn 37, Issue 2, 2014, Pages 77-83

  Fernandez Garcia, Belen ^a   Eiró, Noemí ^a   González Reyes, Salomé ^a   González, Lucía ^a   Aguirre, Alina ^a   González, Luis O ^a,b   Del Casar, José M ^a   García Muñiz, José L ^a   Vizoso, Francisco J ^a  

^a HOSPITAL DE JOVE   (Spain)

^b Servicio de Anatomia Patologica   (Spain)

Author keywords

gastric carcinoma; prognosis; tissue arrays; Toll like receptors; tumor invasion

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; CARCINOGENESIS; CARCINOMA; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9; TUMOR MARKERS, BIOLOGICAL;

EID: 84894469067     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000016     Document Type: Article

References (52)

1. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4:499-511.
2. Moynagh PN. TLR signalling and activation of IRFs: revisiting old friends from the NF-kappa B pathway. Trends Immunol. 2005;26:469-476.
3. Kawai T, Akira S. TLR signaling. Cell Death Differ. 2006;13: 816-825.
4. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Microbes Infect. 2004;6:1382-1387.
5. Matzinger P. An innate sense of danger. Ann N Y Acad Sci. 2002;961:341-342.
6. Gonzalez-Reyes S, Marin L, Gonzalez L, et al. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer. 2010;10:665-673.
7. Alexopoulou L, Holt AC, Medzhitov R, et al. Recognition of double-stranded RNA and activation of NF-kappa B by Tolllike receptor 3. Nature. 2001;413:732-738.
8. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
9. Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. 2001;410:1099-1103.
10. Zhang YB, He FL, Fang M, et al. Increased expression of Tolllike receptors 4 and 9 in human lung cancer. Mol Biol Rep. 2009;36:1475-1481.
11. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
12. Fukata M, Abreu MT. Role of Toll-like receptors in gastrointestinal malignancies. Oncogene. 2008;27:234-243.
13. Hold GL, Rabkin CS, Chow WH, et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology. 2007;132:905-912.
14. Fukata M, Chen A, Vamadevan AS, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology. 2007;133:1869-1881.
15. Swann JB, Vesely MD, Silva A, et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A. 2008; 105:652-656.
16. Ohara T, Morishita T, Suzuki H, et al. Heterozygous Thr 135 Ala polymorphism at leucine-rich repeat (LRR) in genomic DNA of toll-like receptor 4 in patients with poorly-differentiated gastric adenocarcinomas. Int J Mol Med. 2006;18:59-63.
17. Zeng HM, Pan KF, Zhang Y, et al. Genetic variants of toll-like receptor 2 and 5, Helicobacter pylori infection, and risk of gastric cancer and its precursors in a Chinese population. Cancer Epidemiol Biomarkers Prev. 2011;20:2594-2602.
18. Pimentel-Nunes P, Afonso L, Lopes P, et al. Increased expression of toll-like receptors (TLR) 2, 4 and 5 in gastric dysplasia. Pathol Oncol Res. 2011;17:677-683.
19. Pimentel-Nunes P, Goncalves N, Boal-Carvalho I, et al. Helicobacter pylori induces increased expression of Toll-like receptors and decreased Toll-interacting protein in gastric mucosa that persists throughout gastric carcinogenesis. Helicobacter. 2013;18:22-32.
20. Tye H, Kennedy CL, Najdovska M, et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell. 2012;22: 466-478.
21. Gonzalez-Reyes S, Fernandez JM, Gonzalez LO, et al. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother. 2011;60:217-226.
22. Eiro N, Ovies C, Fernandez-Garcia B, et al. Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosis. Arch Dermatol Res. 2013;305:59-67.
23. Eiro N, Gonzalez L, Gonzalez LO, et al. Study of the expression of toll-like receptors in different histological types of colorectal polyps and their relationship with colorectal cancer. J Clin Immunol. 2012;32:848-854.
24. UICC. TNM Classification of Malignant Tumors. 7th ed. Hoboken, NJ: Wiley-Blackwell; 2010.
25. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
26. Vizoso FJ, del Casar JM, Corte MD, et al. Significance of cytosolic hyaluronan levels in gastric cancer. Eur J Surg Oncol. 2004;30:318-324.
27. Parker RL, Huntsman DG, Lesack DW, et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol. 2002;117:723-728.
28. Gonzalez-Reyes S, Fernandez JM, Gonzalez LO, et al. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother. 2011;60:217-226.
29. Gonzalez LO, Corte MD, Vazquez J, et al. Androgen receptor expression in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer. 2008;8: 149-158.
30. Costantini S, Capone F, Guerriero E, et al. An approach for understanding the inflammation and cancer relationship. Immunol Lett. 2009;126:91-92.
31. Sato Y, Goto Y, Narita N, et al. Cancer cells expressing tolllike receptors and the tumor microenvironment. Cancer Microenviron. 2009;2(suppl 1):205-214.
32. Hanahan D, Weinberg. RA. The hallmarks of cancer. Cell. 2000;100:57-70.
33. Huang B, Zhao J, Unkeless JC, et al. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene. 2008;27:218-224.
34. Rakoff-Nahoum S, Medzhitov R. Role of toll-like receptors in tissue repair and tumorigenesis. Biochemistry (Mosc). 2008;73: 555-561.
35. Voelcker V, Gebhardt C, Averbeck M, et al. Hyaluronan fragments induce cytokine and metalloprotease upregulation in human melanoma cells in part by signalling via TLR4. Exp Dermatol. 2008;17:100-107.
36. Inoue J, Aramaki Y. Toll-like receptor-9 expression induced by tape-stripping triggers on effective immune response with CpG- oligodeoxynucleotides. Vaccine. 2007;25:1007-1013.
37. Gonzalez L, Aguirre A, EiroN, et al. Expression and clinical significance of metalloproteases and their inhibitors in gastric cancer. Hepatogastroenterology. 2013. [In press].
38. Schmausser B, Andrulis M, Endrich S, et al. Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol. 2005;295:179-185.
39. Chang YJ, Wu MS, Lin JT, et al. Helicobacter pylori-Induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. J Immunol. 2005;175:8242-8252.
40. Salaun B, Coste I, Rissoan MC, et al. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol. 2006;176: 4894-4901.
41. Shojaei H, Oberg HH, Juricke M, et al. Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells. Cancer Res. 2009;69:8710-8717.
42. Allhorn S, Boing C, Koch AA, et al. TLR3 and TLR4 expression in healthy and diseased human endometrium. Reprod Biol Endocrinol. 2008;6:40-50.
43. Morikawa T, Sugiyama A, Kume H, et al. Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clin Cancer Res. 2007;13:5703-5709.
44. Chin AI, Miyahira AK, Covarrubias A, et al. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res. 2010;70:2595-2603.
45. Amarante MK, de Oliveira KB, Guembarovski RL, et al. Toll-like receptor 3: implications for proinflammatory microenvironment in human breast cancer. Mol Biol Rep. 2012;39: 11087-11092.
46. Edelmann KH, Richardson-Burns S, Alexopoulou L, et al. Does Toll-like receptor 3 play a biological role in virus infections? Virology. 2004;322:231-238.
47. Lore K, Betts MR, Brenchley JM, et al. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirusand HIV-1-specific T cell responses. J Immunol. 2003;171: 4320-4328.
48. Majde JA, Kapas L, Bohnet SG, et al. Attenuation of the influenza virus sickness behavior in mice deficient in Toll-like receptor 3. Brain Behav Immun. 2010;24:306-315.
49. Askar E, Bregadze R, Mertens J, et al. TLR3 gene polymorphisms and liver disease manifestations in chronic hepatitis C. J Med Virol. 2009;81:1204-1211.
50. Sato A, Iizuka M, Nakagomi O, et al. Rotavirus doublestranded RNA induces apoptosis and diminishes wound repair in rat intestinal epithelial cells. J Gastroenterol Hepatol. 2006; 21:521-530.
51. Khan AL, Richardson S, Drew J, et al. Polyadenylicpolyuridylic acid enhances the natural cell-mediated cytotoxicity in patients with breast cancer undergoing mastectomy. Surgery. 1995;118:531-538.
52. Lacour F, Lacour J, Spira A, et al. Adjuvant immunotherapy using polyadenylic acid and polyuridylic acid (Poly A., Poly U.) in operable carcinoma of the breast (author's transl). Chirurgie. 1980;106:737-743.